Glass Pharms, the UK-based cultivator of medical cannabis flower, has announced a supply agreement with Integro Clinic & IPS Pharmacy to provide them with a new premium range of Glass Pharms-branded CBPMs made with domestically grown flower cultivated at the Glass Pharms facility. These will be available from IPS Pharmacy for patients at Integro and Medicann clinics, as well as for patients at other UK clinics
IPS has been prescribing Glass Pharms-derived CBPMs since earlier this year with good patient feedback. This provided confidence to progress in expanding the range with five newly available products based on cultivars produced by the cultivation company.
“We are delighted to announce this direct supply agreement following a period of evaluation where IPS has been prescribing products based on Glass Pharms brand with very positive patient feedback,” said Glass Pharms’ CEO James Duckenfield.
“We look forward to expanding the availability of CBPMs based on cultivars grown by Glass Pharms and adding some new prescribing options that will broaden the range.”
Tony Dutta, CEO of IPS Pharma, added: “We are pleased to be supporting a UK-based supply chain that gives patients surety over continuity of their prescribing needs. Glass Pharms have set out an excellent set of quality standards, achieving microbial standards without irradiation, excellent environmental credentials and zero airmiles. They are also delivering against patient needs with balanced and CBG flowers that can be challenging to fulfil elsewhere.”
Glass Pharms continues to scale production capacities at its 2.4-hectare facility in Wiltshire, which combines best-in-class sustainability credentials with a quality-by-design approach to microbial safety in the production of medical cannabis flower.
The UK medical cannabis market continues to demonstrate healthy growth year-on-year as the supply chain matures, import options become more uncertain and private treatment becomes more affordable.
